Zevra Therapeutics, Inc. Dilutive Share Adjustment
Zevra Therapeutics, Inc. (ZVRA) reported Dilutive Share Adjustment of 2.18 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment · last filed 2026-08-05
- Zevra Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for the quarter ending 2026-06-30 was 2.18M shares, a 41.26% increase year-over-year.
- Zevra Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for the quarter ending 2026-03-31 was 1.82M shares.
- Zevra Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-12-31 was 2.31M shares.
- Zevra Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for the quarter ending 2025-09-30 was 0.00 shares.
- Zevra Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for fiscal 2025 was 1.95M shares.
- Zevra Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for fiscal 2024 was 0.00 shares.
| Period end | Weighted Average Number Diluted Shares Outstanding Adjustment 3 month | Weighted Average Number Diluted Shares Outstanding Adjustment 6 month | Weighted Average Number Diluted Shares Outstanding Adjustment 9 month | Weighted Average Number Diluted Shares Outstanding Adjustment 12 month |
|---|---|---|---|---|
| 2026-06-30 | 2.18M shares 10-Q · filed 2026-08-05 | 2.00M shares 10-Q · filed 2026-08-05 | 2.10M shares derived: average of 3 quarters · filed 2026-08-05 | 1.58M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 1.82M shares 10-Q · filed 2026-05-06 | 2.07M shares derived: average of 2 quarters · filed 2026-05-06 | 1.38M shares derived: average of 3 quarters · filed 2026-05-06 | 1.42M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 2.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 1.15M shares derived: average of 2 quarters · filed 2026-03-09 | 1.28M shares derived: average of 3 quarters · filed 2026-08-05 | 1.95M shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-05 | 772.00K shares derived: average of 2 quarters · filed 2026-08-05 | 1.83M shares 10-Q · filed 2025-11-05 | |
| 2025-06-30 | 1.54M shares 10-Q · filed 2026-08-05 | 1.62M shares 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 0.00 shares 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |